Cite
Suzuki R, Takagi T, Hikichi T, et al. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncol Lett. 2016;11(5):3441-3445doi: 10.3892/ol.2016.4381.
Suzuki, R., Takagi, T., Hikichi, T., Konno, N., Sugimoto, M., Watanabe, K. O., Nakamura, J., Waragai, Y., Kikuchi, H., Takasumi, M., Watanabe, H., & Ohira, H. (2016). Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncology letters, 11(5), 3441-3445. https://doi.org/10.3892/ol.2016.4381
Suzuki, Rei, et al. "Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer." Oncology letters vol. 11,5 (2016): 3441-3445. doi: https://doi.org/10.3892/ol.2016.4381
Suzuki R, Takagi T, Hikichi T, Konno N, Sugimoto M, Watanabe KO, Nakamura J, Waragai Y, Kikuchi H, Takasumi M, Watanabe H, Ohira H. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Oncol Lett. 2016 May;11(5):3441-3445. doi: 10.3892/ol.2016.4381. Epub 2016 Mar 29. PMID: 27123132; PMCID: PMC4840986.
Copy
Download .nbib